The Week In... Pharma (12-16/11)
  • Posted on: 16/11/2018
  • Category: Industry

The Week In... Pharma (12-16/11)

In a hurry? Find top global pharma news right here! This week we’re featuring articles including cases of measles increasing in the UK, Australians calling for more privacy with their medical information, a WHO report mapping global antibiotic use, and concerns within pharma over a no-deal Brexit. Take a look!

Interested in Star’s innovative outsourcing and resourcing solutions?

Contact Head of Business Development, Ryan Wooller, at, or get in touch on 07748 464 079.

On the hunt for a new role, or just curious?

Visit our candidate page, submit your CV to, or give our offices a ring!

Cases of measles nearly quadruple since last year in UK

Public Health England is urging the public to ensure that they have received two doses of the MMR vaccine after it was revealed that there were more than 913 cases of measles between January the 1st and October 31st 2018, compared to the 259 that occurred across the whole of 2017.

Brexit wasting time and money, say Welsh pharma companies

Drug companies in Wales have said that Brexit is wasting time and money that could be otherwise spent on developing new medicines. The BBC reports on Wales putting together “robust plans” in case of a no-deal Brexit.

Australians need more time to opt-out of My Health Record, say politicians

Australia’s Senate has passed a motion calling on the government to extend an opt-out period for its controversial My Health Record scheme, which has been dogged by concerns about privacy.

Patients and industry fret over drug supplies, if no Brexit deal

Consumers and the pharma industry alike are anxious about medicine supplies, if there is no deal on Britain's departure from the European Union.

WHO uncovers big national variations in antibiotics consumption

Antibiotics are used far more in some countries than in others, a survey by the World Health Organisation has shown, suggesting that urgent action is needed to slash unnecessary consumption of the medicines. 

While you’re here…

…and are interested in our content, why not sign up to our newsletter? It’s just below here.